 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CARBAMAZEPINE increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CARBAMAZEPINE increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CARBAMAZEPINE increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CARBAMAZEPINE increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CARBAMAZEPINE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"carbamazepine"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CARBAMAZEPINE: adverse_reactions: The following additional adverse reactions were previously reported with carbamazepine: Hemopoietic System: Aplastic anemia, agranulocytosis, pancytopenia, [0m
[31mbone marrow depression, thrombocytopenia, leukopenia, leukocytosis, eosinophilia, acute intermittent porphyria. Skin: Toxic epidermal necrolysis [0m[1;31m([0m[31mTEN[0m[1;31m)[0m[31m and Stevens-Johnson syndrome [0m[1;31m([0m[31mSJS[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee BOXED [0m
[31mWARNING [0m[1;31m)[0m[31m, Acute Generalized Exanthematous Pustulosis [0m[1;31m([0m[31mAGEP[0m[1;31m)[0m[31m, pruritic and erythematous rashes, urticaria, photosensitivity reactions, alterations in skin pigmentation, exfoliative dermatitis, [0m
[31merythema multiforme and nodosum, purpura, aggravation of disseminated lupus erythematosus, alopecia, diaphoresis, onychomadesis and hirsutism. CARBAMAZEPINE: adverse_reactions: In certain cases, [0m
[31mdiscontinuation of therapy may be necessary. Cardiovascular System : Congestive heart failure, edema, aggravation of hypertension, hypotension, syncope and collapse, aggravation of coronary artery [0m
[31mdisease, arrhythmias and AV block, thrombophlebitis, thromboembolism, and adenopathy or lymphadenopathy. Some of these cardiovascular complications have resulted in fatalities. Myocardial infarction [0m
[31mhas been associated with other tricyclic compounds. Immune system disorders : Hypogammaglobulinemia. Liver : Abnormalities in liver function tests, cholestatic and hepatocellular jaundice, hepatitis, [0m
[31mand hepatic failure. Pancreatic : Pancreatitis. Respiratory System: Pulmonary hypersensitivity characterized by fever, dyspnea, pneumonitis, or pneumonia. CARBAMAZEPINE: adverse_reactions: [0m
[31mGenitourinary System : Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, azotemia, renal failure, and impotence. Albuminuria, glycosuria, elevated BUN, and microscopic[0m
[31mdeposits in the urine have also been reported. There have been rare reports of impaired male fertility and/or abnormal spermatogenesis. Testicular atrophy occurred in rats receiving carbamazepine [0m
[31morally from [0m[1;31m4[0m[31m to [0m[1;31m52[0m[31m weeks at dosage levels of [0m[1;31m50[0m[31m to [0m[1;31m400[0m[31m mg/kg/day. Additionally, rats receiving carbamazepine in the diet for [0m[1;31m2[0m[31m years at dosage levels of [0m[1;31m25[0m[31m, [0m[1;31m75[0m[31m, and [0m[1;31m250[0m[31m mg/kg/day had a dose-related [0m
[31mincidence of testicular atrophy and aspermatogenesis. In dogs, it produced a brownish discoloration, presumably a metabolite, in the urinary bladder at dosage levels of [0m[1;31m50[0m[31m mg/kg/day and higher. [0m
[31mRelevance of these findings to humans is unknown. CARBAMAZEPINE: adverse_reactions: Nervous System : Dizziness, drowsiness, disturbances of coordination, confusion, headache, fatigue, blurred vision, [0m
[31mvisual hallucinations, transient diplopia, oculomotor disturbances, nystagmus, speech disturbances, abnormal involuntary movements, peripheral neuritis and paresthesias, depression with agitation, [0m
[31mtalkativeness, tinnitus, and hyperacusis. There have been reports of associated paralysis and other symptoms of cerebral arterial insufficiency, but the exact relationship of these reactions to the [0m
[31mdrug has not been established. Isolated cases of neuroleptic malignant syndrome have been reported with concomitant use of psychotropic drugs. Digestive System : Nausea, vomiting, gastric distress and[0m
[31mabdominal pain, diarrhea, constipation, anorexia, and dryness of the mouth and pharynx, including glossitis and stomatitis. Eyes: Scattered punctate cortical lens opacities, as well as conjunctivitis,[0m
[31mhave been reported. CARBAMAZEPINE: adverse_reactions: Although a direct causal relationship has not been established, many phenothiazines and related drugs have been shown to cause eye changes. [0m
[31mMusculoskeletal System: Bone loss, aching joints and muscles, and leg cramps. Metabolism : Fever and chills, decreased levels of plasma calcium leading to osteoporosis, and hyperammonemia have been [0m
[31mreported. Other: Isolated cases of a lupus erythematosus-like syndrome have been reported. There have been occasional reports of elevated levels of cholesterol, HDL cholesterol, and triglycerides in [0m
[31mpatients taking anticonvulsants. A case of aseptic meningitis, accompanied by myoclonus and peripheral eosinophilia, has been reported in a patient taking carbamazepine in combination with other [0m
[31mmedications. The patient was successfully dechallenged, and the meningitis reappeared upon rechallenge with carbamazepine.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: laboratory_tests: Laboratory Tests For genetically at-risk patients [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m, high-resolution â€˜ HLA-B*[0m[1;31m1502[0m[31m typing â€™ is recommended. The test is positive if either one or[0m
[31mtwo HLA-B*[0m[1;31m1502[0m[31m alleles are detected and negative if no HLA-B*[0m[1;31m1502[0m[31m alleles are detected. Complete pretreatment blood counts, including platelets and possibly reticulocytes and serum iron, should be [0m
[31mobtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of the drug [0m
[31mshould be considered if any evidence of significant bone marrow depression develops. Baseline and periodic evaluations of liver function, particularly in patients with a history of liver disease, must[0m
[31mbe performed during treatment with this drug since liver damage may occur [0m[1;31m([0m[31msee PRECAUTIONS , General and ADVERSE REACTIONS , Liver [0m[1;31m)[0m[31m. CARBAMAZEPINE: laboratory_tests: Carbamazepine extended-release [0m
[31mcapsules should be discontinued based on clinical judgement, if indicated by newly occurring or worsening clinical or laboratory evidence of liver dysfunction or hepatic damage, or in the case of [0m
[31mactive liver disease. Baseline and periodic eye examinations, including slit-lamp, funduscopy, and tonometry, are recommended since many phenothiazines and related drugs have been shown to cause eye [0m
[31mchanges. Baseline and periodic complete urinalysis and BUN determinations are recommended for patients treated with this agent because of observed renal dysfunction. Increases in total cholesterol, [0m
[31mLDL and HDL have been observed in some patients taking anticonvulsants. Therefore, periodic evaluation of these parameters is also recommended. Monitoring of blood levels [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY [0m[1;31m)[0m[31m [0m
[31mhas increased the efficacy and safety of anticonvulsants. This monitoring may be particularly useful in cases of dramatic increase in seizure frequency and for verification of compliance. [0m
[31mCARBAMAZEPINE: laboratory_tests: In addition, measurement of drug serum levels may aid in determining the cause of toxicity when more than one medication is being used. Thyroid function tests have [0m
[31mbeen reported to show decreased values with carbamazepine administered alone. Interference with some pregnancy tests has been reported.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: openfda: pharm_class_pe         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: drug_interactions: ketoconazole, itraconazole, fluconazole, voriconazole[0m[1;31m)[0m[31m, cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem,[0m
[31merythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, macrolides, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, protease inhibitors, [0m
[31mpropoxyphene, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil, zileuton. CARBAMAZEPINE: drug_interactions: Human microsomal epoxide hydrolase has been identified as the enzyme[0m
[31mresponsible for the formation of the [0m[1;31m10[0m[31m,[0m[1;31m11[0m[31m-transdiol derivative from carbamazepine-[0m[1;31m10[0m[31m,[0m[1;31m11[0m[31m epoxide. Coadministration of inhibitors of human microsomal epoxide hydrolase may result in increased [0m
[31mcarbamazepine-[0m[1;31m10[0m[31m,[0m[1;31m11[0m[31m epoxide plasma concentrations. Accordingly, the dosage of carbamazepine extended-release capsules should be adjusted and/or the plasma levels monitored when used concomitantly with[0m
[31mloxapine, quetiapine, or valproic acid. Thus, if a patient has been titrated to a stable dosage of carbamazepine extended-release capsules, and then begins a course of treatment with one of these [0m
[31mCYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for carbamazepine extended-release capsules may be necessary. CARBAMAZEPINE: drug_interactions: Agents that [0m
[31mInduce Cytochrome P450 Isoenzymes : Carbamazepine is metabolized by CYP3A4. Therefore, the potential exists for interaction between carbamazepine and any agent that induces CYP3A4. Agents that are CYP[0m
[31minducers that have been found, or are expected, to decrease plasma levels of carbamazepine extended-release capsules include, for example, the following: Aminophylline, cisplatin, doxorubicin HCL, [0m
[31mfelbamate, fosphenytoin, methsuximide, phenobarbital, [0m[1;31mphenytoin[0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m, primidone, rifampin and theophylline. [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Phenytoin plasma levels have also been reported to increase and decrease in the presence[0m
[31mof carbamazepine, see below. CARBAMAZEPINE: drug_interactions: Thus, if a patient has been titrated to a stable dosage on carbamazepine extended-release capsules, and then begins a course of treatment[0m
[31mwith one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for carbamazepine extended-release capsules may be necessary. Agents with Decreased Levels in the Presence of [0m
[31mCarbamazepine due to Induction of Cytochrome P450 Enzymes: Carbamazepine is a potent inducer of hepatic CYP3A4 and is also known to be an inducer of CYP1A2, 2B6, 2C9/[0m[1;31m19[0m[31m and may therefore reduce plasma[0m
[31mconcentrations of co-medications mainly metabolized by CYP 1A2, 2B6, 2C9/[0m[1;31m19[0m[31m and 3A4, through induction of their metabolism. CARBAMAZEPINE: drug_interactions: When used concomitantly with carbamazepine[0m
[31mextended-release capsules, monitoring of concentrations or dosage adjustment of these agents may be necessary: When carbamazepine is added to aripiprazole, the aripiprazole dose should be doubled. [0m
[31mAdditional dose increases should be based on clinical evaluation. If carbamazepine is later withdrawn, the aripiprazole dose should be reduced. When carbamazepine is used with tacrolimus, monitoring [0m
[31mof tacrolimus blood concentrations and appropriate dosage adjustments are recommended. The use of concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. If [0m
[31mpatients must be coadministered carbamazepine with temsirolimus, an adjustment of temsirolimus dosage should be considered. The use of carbamazepine with lapatinib should generally be avoided. [0m
[31mCARBAMAZEPINE: drug_interactions: If carbamazepine is started in a patient already taking lapatinib, the dose of lapatinib should be gradually titrated up. If carbamazepine is discontinued, the [0m
[31mlapatinib dose should be reduced. Concomitant use of carbamazepine with nefazodone results in plasma concentrations of nefazodone and its active metabolite insufficient to achieve a therapeutic [0m
[31meffect. Coadministration of carbamazepine with nefazodone is contraindicated [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Monitor concentrations of valproate when carbamazepine extended-release capsules are introduced [0m
[31mor withdrawn in patients using valproic acid. CARBAMAZEPINE: drug_interactions: In addition, carbamazepine causes, or would be expected to cause, decreased levels of, for example, the following drugs,[0m
[31mfor which monitoring of concentrations or dosage adjustment may be necessary: Acetaminophen, albendazole, alprazolam, aprepitant, buprenorphine, [0m[1;31mapixaban[0m[1;31m([0m[31m [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m, bupropion, buspirone, citalopram, [0m
[31mclobazam, clonazepam, clozapine, corticosteroids [0m[1;31m([0m[31me.g. prednisolone, dexamethasone[0m[1;31m)[0m[31m, cyclosporin, [0m[1;31mdabigatran[0m[1;31m([0m[31m [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel [0m
[31mblockers [0m[1;31m([0m[31me.g. CARBAMAZEPINE: drug_interactions: felodipine[0m[1;31m)[0m[31m, doxycycline, [0m[1;31medoxaban[0m[1;31m([0m[31m [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m, eslicarbazepine, ethosuximide, everolimus, felbamate, haloperidol, imatinib, itraconazole, lamotrigine, [0m
[31mlevothyroxine, lorazepam, methadone, methsuximide, midazolam, mirtazapine, nefazodone, nortriptyline, olanzapine, oral and other hormonal [0m[1;31mcontraceptives[0m[1;31m([0m[31m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m, oxcarbazepine, paliperidone, [0m[1;31mphenytoin[0m[1;31m([0m[31m [0m[1;31m3[0m
[1;31m)[0m[31m, praziquantel, protease inhibitors, quetiapine, risperidone, [0m[1;31mrivaroxaban[0m[1;31m([0m[31m [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m, sertraline, sirolimus, tadalafil, theophylline, tiagabine, topiramate, tramadol, triazolam, trazodone CARBAMAZEPINE: [0m
[31mdrug_interactions: [0m[1;31m([0m[31m [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m, tricyclic antidepressants [0m[1;31m([0m[31me.g., imipramine, amitriptyline, nortriptyline[0m[1;31m)[0m[31m, valproate, warfarin [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m , ziprasidone, and zonisamide. [0m[1;31m([0m[31m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m Concomitant use of carbamazepine with[0m
[31mhormonal contraceptive products [0m[1;31m([0m[31me.g., oral and levonorgestrel subdermal implant contraceptives[0m[1;31m)[0m[31m may render the contraceptives less effective because the plasma concentrations of the hormones may be [0m
[31mdecreased. Breakthrough bleeding and unintended pregnancies have been reported with carbamazepine. Alternative or back-up methods of contraception should be considered. [0m[1;31m([0m[31m [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m Phenytoin has also been [0m
[31mreported to increase in the presence of carbamazepine. Careful monitoring of phenytoin plasma levels following co-medication with carbamazepine is advised. CARBAMAZEPINE: drug_interactions: [0m[1;31m([0m[31m [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m [0m
[31mFollowing co-administration of carbamazepine [0m[1;31m400[0m[31m mg/day with trazodone [0m[1;31m100[0m[31m mg to [0m[1;31m300[0m[31m mg daily, carbamazepine reduced trough plasma concentrations of trazodone [0m[1;31m([0m[31mas well as meta-chlorophenylpiperazine [0m[1;31m)[0m
[31mby [0m[1;31m76[0m[31m and [0m[1;31m60[0m[31m% respectively, compared to precarbamazepine values. [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m Warfarinâ€™s anticoagulant effect can be reduced in the presence of carbamazepine. [0m[1;31m([0m[1;31m6[0m[1;31m)[0m[31m Concomitant use of carbamazepine with [0m
[31mrivaroxaban, apixaban, dabigatran, and edoxaban [0m[1;31m([0m[31mdirect acting oral anticoagulants[0m[1;31m)[0m[31m is expected to result in decreased plasma concentrations of these anticoagulants that may be insufficient to achieve[0m
[31mthe intended therapeutic effect. CARBAMAZEPINE: drug_interactions: In general, coadministration of carbamazepine with rivaroxaban, apixaban, dabigatran, and edoxaban should be avoided. Thus, if a [0m
[31mpatient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with carbamazepine extended-release capsules, it is reasonable to expect that [0m
[31ma dose increase for the concomitant agent may be necessary. Agents with Increased Levels in the Presence of Carbamazepine Carbamazepine extended-release capsules increase the plasma levels of the [0m
[31mfollowing agents. Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with carbamazepine extended-release capsules,[0m
[31mit is reasonable to expect that a dose decrease for the concomitant agent may be necessary. CARBAMAZEPINE: drug_interactions: Clomipramine HCl, [0m[1;31mPhenytoin[0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m, and Primidone Carbamazepine [0m
[31mextended-release capsules can increase the concentrations of clomipramine, phenytoin, and primidone. If a patient has been titrated to a stable dosage on one of these agents in this category, and then[0m
[31mbegins treatment with carbamazepine extended-release capsules, it may be necessary to decrease the dose of these drugs. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31mPhenytoin has also been reported to decrease in the presence of [0m
[31mcarbamazepine. Careful monitoring of phenytoin plasma levels following co-medication with carbamazepine is advised. Cyclophosphamide Cyclophosphamide is an inactive prodrug and is converted to its [0m
[31mactive metabolite in part by CYP3A. CARBAMAZEPINE: drug_interactions: The rate of metabolism and the leukopenic activity of cyclophosphamide are reportedly increased by chronic co-administration of [0m
[31mCYP3A4 inducers. There is a potential for increased cyclophosphamide toxicity when coadministered with carbamazepine. Pharmacological/Pharmacodynamic Interactions with Carbamazepine: Delavirdine [0m
[31mCoadministration of carbamazepine with delavirdine may lead to loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors [0m[1;31m([0m[31msee[0m
[31mCONTRAINDICATIONS [0m[1;31m)[0m[31m. Lithium Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects. Thyroid Effects with Other Anticonvulsant Medications Alterations[0m
[31mof thyroid function have been reported in combination therapy with other anticonvulsant medications. CARBAMAZEPINE: drug_interactions: Chloroquine and Mefloquine Anti-malarial drugs, such as [0m
[31mchloroquine and mefloquine, may antagonize the activity of carbamazepine. Thus if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of [0m
[31mtreatment with carbamazepine extended-release capsules, it is reasonable to expect that a dose adjustment may be necessary. CNS Depressants The concomitant use of carbamazepine extended-release [0m
[31mcapsules and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: warnings: WARNINGS Serious Dermatologic Reactions Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis [0m[1;31m([0m[31mTEN[0m[1;31m)[0m[31m and Stevens-Johnson syndrome [0m
[1;31m([0m[31mSJS[0m[1;31m)[0m[31m, have been reported with carbamazepine treatment. The risk of these events is estimated to be about [0m[1;31m1[0m[31m to [0m[1;31m6[0m[31m per [0m[1;31m10[0m[31m,[0m[1;31m000[0m[31m new users in countries with mainly Caucasian populations. However, the risk [0m
[31min some Asian countries is estimated to be about [0m[1;31m10[0m[31m times higher. Carbamazepine extended-release capsules should be discontinued at the first sign of a rash, unless the rash is clearly not [0m
[31mdrug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered. CARBAMAZEPINE: warnings: SJS/TEN and HLA-B*[0m[1;31m1502[0m[31m Allele [0m
[31mRetrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of[0m
[31man inherited variant of the HLA-B gene, HLA-B*[0m[1;31m1502[0m[31m. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in [0m
[31mallele-positive individuals of any ethnicity. Across Asian populations, notable variation exists in the prevalence of HLA-B*[0m[1;31m1502[0m[31m. Greater than [0m[1;31m15[0m[31m% of the population is reported positive in Hong Kong, [0m
[31mThailand, Malaysia, and parts of the Philippines, compared to about [0m[1;31m10[0m[31m% in Taiwan and [0m[1;31m4[0m[31m% in North China. South Asians, including Indians, appear to have intermediate prevalence of HLA-B*[0m[1;31m1502[0m[31m, [0m
[31maveraging [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m%, but higher in some groups. CARBAMAZEPINE: warnings: HLA-B*[0m[1;31m1502[0m[31m is present in <[0m[1;31m1[0m[31m% of the population in Japan and Korea. HLA-B*[0m[1;31m1502[0m[31m is largely absent in individuals not of Asian [0m
[31morigin [0m[1;31m([0m[31me.g., Caucasians, African-Americans, Hispanics, and Native Americans[0m[1;31m)[0m[31m. Prior to initiating carbamazepine extended-release capsules therapy, testing for HLA-B*[0m[1;31m1502[0m[31m should be performed in [0m
[31mpatients with ancestry in populations in which HLA-B*[0m[1;31m1502[0m[31m may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*[0m[1;31m1502[0m[31m may offer a rough guide, [0m
[31mkeeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry. [0m
[31mCarbamazepine extended-release capsules should not be used in patients positive for HLA-B*[0m[1;31m1502[0m[31m unless the benefits clearly outweigh the risks. CARBAMAZEPINE: warnings: Tested patients who are found to[0m
[31mbe negative for the allele are thought to have a low risk of SJS/TEN [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS/Laboratory Tests [0m[1;31m)[0m[31m. Over [0m[1;31m90[0m[31m% of carbamazepine treated patients who will experience SJS/TEN have this [0m
[31mreaction within the first few months of treatment. This information may be taken into consideration in determining the need for screening of genetically at-risk patients currently on carbamazepine [0m
[31mextended-release capsules. The HLA-B*[0m[1;31m1502[0m[31m allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as maculopapular eruption [0m[1;31m[[0m[31mMPE[0m[1;31m][0m[31m or to predict [0m
[31mDrug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m. CARBAMAZEPINE: warnings: Limited evidence suggests that HLA-B*[0m[1;31m1502[0m[31m may be a risk factor for the development of SJS/TEN in patients of [0m
[31mChinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B*[0m[1;31m1502[0m[31m [0m
[31mpositive patients, when alternative therapies are otherwise equally acceptable. Patients should be made aware that carbamazepine extended-release capsules contain carbamazepine and should not be used [0m
[31min combination with any other medications containing carbamazepine. Hypersensitivity Reactions and HLA-A*[0m[1;31m3101[0m[31m Allele Retrospective case-control studies in patients of European, Korean, and Japanese [0m
[31mancestry have found a moderate association between the risk of developing hypersensitivity reactions and the presence of HLA-A*[0m[1;31m3101[0m[31m, an inherited allelic variant of the HLA-A gene, in patients using [0m
[31mcarbamazepine. CARBAMAZEPINE: warnings: These hypersensitivity reactions include SJS/TEN, maculopapular eruptions, and Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31msee DRESS/Multiorgan [0m
[31mhypersensitivity below[0m[1;31m)[0m[31m. HLA-A*[0m[1;31m3101[0m[31m is expected to be carried by more than [0m[1;31m15[0m[31m% of patients of Japanese, Native American, Southern Indian [0m[1;31m([0m[31me.g., Tamil Nadu[0m[1;31m)[0m[31m and some Arabic ancestry; up to about [0m[1;31m10[0m[31m% in[0m
[31mpatients of Han Chinese, Korean, European, Latin American and other Indian ancestry; and up to about [0m[1;31m5[0m[31m% in African-Americans and patients of Thai, Taiwanese, and Chinese [0m[1;31m([0m[31mHong Kong[0m[1;31m)[0m[31m ancestry. The [0m
[31mrisks and benefits of carbamazepine therapy should be weighed before considering carbamazepine in patients known to be positive for HLA-A*[0m[1;31m3101[0m[31m. General Information on HLA Genotyping and [0m
[31mHypersensitivity Application of HLA genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Carbamazepine has been reported to cause renal failure as an adverse reaction. Specifically, the adverse reactions section of the carbamazepine label lists [0m[32m"renal failure"[0m[32m under genitourinary [0m
[32msystem adverse reactions. Additionally, it mentions urinary frequency, acute urinary retention, oliguria with elevated blood pressure, azotemia, and other related issues. It is important to note that [0m
[32mthese are potential adverse reactions and do not necessarily occur in all patients taking carbamazepine.[0m

[32mSOURCE: CARBAMAZEPINE label[0m
[32mEXTRACT_START_END: Genitourinary System: Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, azotemia, renal failure[0m[32m...[0m
*[1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Carbamazepine has been reported to cause renal failure as an [0m
[34madverse reaction. Specifically, the adverse reactions section of the carbamazepine label lists [0m[34m"renal failure"[0m[34m under genitourinary system adverse reactions. Additionally, it mentions urinary [0m
[34mfrequency, acute urinary retention, oliguria with elevated blood pressure, azotemia, and other related issues. It is important to note that these are potential adverse reactions and do not necessarily[0m
[34moccur in all patients taking carbamazepine.[0m

[34mSOURCE: CARBAMAZEPINE label[0m
[34mEXTRACT_START_END: Genitourinary System: Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, azotemia, renal failure[0m[34m...[0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CARBAMAZEPINE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CARBAMAZEPINE increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that CARBAMAZEPINE has been reported to cause renal failure as an adverse reaction, and it is listed under genitourinary system adverse reactions in the drug label."[0m[32m,[0m
[32m      [0m[32m"It is also noted that these are potential adverse reactions and do not necessarily occur in all patients taking carbamazepine."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"CARBAMAZEPINE has been reported to increase the risk of renal failure as an adverse reaction according to its drug label. However, this does not necessarily occur in all patients and is[0m
[32ma potential adverse reaction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CARBAMAZEPINE increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CARBAMAZEPINE increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that CARBAMAZEPINE has been reported to cause renal failure as an adverse reaction, and it is listed under genitourinary system adverse reactions in the drug label."[0m[34m,[0m
[34m      [0m[34m"It is also noted that these are potential adverse reactions and do not necessarily occur in all patients taking carbamazepine."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"CARBAMAZEPINE has been reported to increase the risk of renal failure as an adverse reaction according to its drug label. However, this does not necessarily occur in all patients and is[0m
[34ma potential adverse reaction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CARBAMAZEPINE increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CARBAMAZEPINE increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded that CARBAMAZEPINE has been reported to cause renal failure as an adverse reaction, and it is listed under genitourinary system adverse reactions in the drug label.[0m
[1;31m3[0m[31m. It is also noted that these are potential adverse reactions and do not necessarily occur in all patients taking carbamazepine.[0m
[31m        -----[0m
[31m        Final answer: CARBAMAZEPINE has been reported to increase the risk of renal failure as an adverse reaction according to its drug label. However, this does not necessarily occur in all patients[0m
[31mand is a potential adverse reaction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-CARBAMAZEPINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does CARBAMAZEPINE increase or decrease the risk of renal failure?"[0m[32m is that CARBAMAZEPINE has been reported to increase the risk of renal failure as an adverse [0m
[32mreaction according to its drug label. However, it is important to note that this is a potential adverse reaction and does not necessarily occur in all patients taking the medication.[0m
